At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
Elotuzumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
In Brief
A Phase 2 clinical trial evaluating Elotuzumab, Pomalidomide, and 2 other interventions for Multiple Myeloma. Completed, enrolled 74 participants across 22 sites.
Detailed Summary
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartFeb 2016
Primary CompletionJul 2019
Study CompletionJun 2020
TodayJul 2026
First PostedNov 24, 2015
Enrollment StartFeb 9, 2016
Primary CompletionJul 29, 2019
Study CompletionJun 12, 2020
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.6 years ago
Interventions
Elotuzumabdrug
Pomalidomidedrug
Dexamethasonedrug
Nivolumabdrug